Almac
Almac Group, often referred to simply as Almac, is a leading global contract development and manufacturing organisation headquartered in the United States. Established in 2004, Almac has expanded its operational footprint across key regions, including Europe and Asia, solidifying its presence in the pharmaceutical and biotechnology sectors. Specialising in drug development, clinical trial services, and commercial manufacturing, Almac distinguishes itself through its innovative solutions and commitment to quality. The company has achieved significant milestones, including the successful launch of numerous life-saving therapies, positioning itself as a trusted partner for clients in the healthcare industry. With a strong emphasis on customer collaboration and cutting-edge technology, Almac continues to enhance its market position, making a notable impact on the global landscape of drug development and manufacturing.
DitchCarbon Score
How does Almac's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Almac's score of 43 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Almac's reported carbon emissions
In 2023, Almac Group reported total carbon emissions of approximately 12728000 kg CO2e for Scope 1, 17434000 kg CO2e for Scope 2, and a significant 133895000 kg CO2e for Scope 3 emissions. This reflects a comprehensive approach to emissions reporting, covering all three scopes of greenhouse gas emissions. Almac has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 emissions by 50% by 2030, using 2019 as the baseline year. Additionally, the company has pledged to achieve net-zero emissions across all scopes by 2045. This long-term target aligns with industry standards for climate action and reflects a commitment to sustainability within the pharmaceutical sector. In terms of specific initiatives, Almac is also targeting a 27.5% reduction in absolute Scope 3 emissions by 2030. Furthermore, for long-term goals, the company aims for a 95% reduction in Scope 1 and 2 emissions by 2045, alongside a 90% reduction in Scope 3 emissions. These commitments demonstrate Almac's proactive stance in addressing climate change and its dedication to reducing its carbon footprint in line with global sustainability goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 13,675,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 19,146,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 149,516,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Almac is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
